Abstract
Recent emerging biochemical data indicate that several important neuroregulatory genes and proteins may be involved in the etiology of schizophrenia and bipolar disorder. Additionally, the same genes appear to be targets of several psychotropic medications that are used to treat these disorders. Recent DNA microarray studies show that genes involved in synaptic neurotransmission, signal transduction, and glutamate/GABA regulation may be differentially regulated in brains of subjects with schizophrenia. We hypothesized that chronic administration of olanzapine to rats would alter expression of various genes that may be involved in the etiology of schizophrenia and mood disorders. Rats were administered olanzapine (N=20, 2 mg/kg/day) or sterile saline intraperitoneally (N=20) daily for 21 days. Control and olanzapine-treated frontal cortices were analyzed using cDNA microarray technology. The results showed significant downregulation of 31 genes and upregulation of 38 genes by greater than two-fold in the drug-treated brains vs controls. Our results provide evidence for altered regulation of genes involved with signal transduction and cell communication, metabolism and energy pathways, transport, immune response, nucleic acid metabolism, and neuronal growth factors. Real-time quantitative RT-PCR analysis verified the direction and magnitude of change in six genes of interest: calbindin 3, homer 1, regulator of G-protein signaling (RGS) 2, pyruvate kinase, Reelin and insulin 2. Western blotting showed significant upregulation in protein products for Reelin 410 and Reelin 180 kDa and downregulation for NMDA3B and RGS2. Our results show for the first time that olanzapine causes changes in levels of several important genes that may be involved in the etiology and treatment of schizophrenia and other psychiatric disorders.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Angelucci F, Aloe L, Iannitelli A, Gruber SH, Mathe AA (2005). Effect of chronic olanzapine treatment on nerve growth factor and brain-derived neurotrophic factor in the rat brain. Eur Neuropsychopharmacol 15: 311–317.
Beffert U, Weeber EJ, Durudas A, Qiu S, Masiulis I, Sweatt JD et al (2005). Modulation of synaptic plasticity and memory by reelin involves differential splicing of the lipoprotein receptor apoer2. Neuron 47: 567–579.
Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT et al (1997). In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 58 (Suppl 10): 28–36.
Chen ML, Chen CH (2005). Microarray analysis of differentially expressed genes in rat frontal cortex under chronic risperidone treatment. Neuropsychopharmacology 30: 268–277.
Chong VZ, Costain W, Marriott J, Sindwani S, Knauer DJ, Wang JF et al (2004). Differential display polymerase chain reaction reveals increased expression of striatal rat glia-derived nexin following chronic clozapine treatment. Pharmacogenomics J 4: 379–387.
Chong VZ, Young LT, Mishra RK (2002). cDNA array reveals differential gene expression following chronic neuroleptic administration: implications of synapsin II in haloperidol treatment. J Neurochem 82: 1533–1539.
DeLisi LE, Shaw SH, Crow TJ, Shields G, Smith AB, Larach VW et al (2002). A genome wide scan for linkage to chromosomal regions in 382 sibling pairs with schizophrenia or schizoaffective disorder. Am J Psychiatry 159: 803–812.
Doublier S, Duyckaerts C, Seurin D, Binoux M (2000). Impaired brain development and hydrocephalus in a line of transgenic mice with liver-specific expression of human insulin-like growth factor binding protein-1. Growth Horm IGF Res 10: 267–274.
Elshatory Y, Brooks AI, Chattopadhyay S, Curran TM, Gupta P, Ramalingam V et al (2003). Early changes in gene expression in two models of Batten disease. FEBS Lett 538: 207–212.
Evans SJ, Choudary PV, Neal CR, Li JZ, Vawter MP, Tomita H et al (2004). Dysregulation of the fibroblast growth factor system in major depression. Proc Natl Acad Sci USA 101: 15506–15511.
Fatemi SH (2005). Reelin glycoprotein: structure, biology and roles in health and disease. Molecular Psychiatry 10: 251–257.
Fatemi SH, Earle JA, McMenomy T (2000). Reduction in Reelin immunoreactivity in hippocampus of subjects with schizophrenia, bipolar disorder and major depression. Mol Psychiatry 5: 654–663.
Fatemi SH, Kroll JL, Stary JM (2001b). Altered levels of Reelin and its isoforms in schizophrenia and mood disorders. Neuroreport 12: 3209–3215.
Fatemi SH, Meltzer HY (2000). Binding of olanzapine to serotonin receptors. In: Tran PV, Bymaster FP, Tye N, Herrera JM, Breier A, Tollefson GD (eds). Olanzapine (Zyprexa): A Novel Antipsychotic. Lippincott, Williams and Wilkins: Baltimore, MD. pp 25–30.
Fatemi SH, Pearce DA, Brooks AI, Sidwell RW (2005c). Prenatal viral infection in mouse causes differential expression of genes in brains of mouse progeny: a potential animal model for schizophrenia and autism. Synapse 57: 91–99.
Fatemi SH, Snow AV, Stary JM, Araghi-Niknam M, Reutiman TJ, Lee S et al (2005b). Reelin signaling is impaired in autism. Biol Psychiatry 57: 777–787.
Fatemi SH, Stary JM, Egan EA (2002). Reduced blood levels of Reelin as a vulnerability factor in pathophysiology of autistic disorder. Cell Mol Neurobiol 22: 139–152.
Fatemi SH, Stary JM, Earle JA, Araghi-Niknam M, Eagan E (2005a). GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and Reelin proteins in cerebellum. Schizophr Res 72: 109–122.
Fatemi SH, Stary JM, Halt AR, Realmuto GR (2001a). Dysregulation of Reelin and bcl-2 proteins in autistic cerebellum. Autism Dev Disord 31: 529–535.
Ferguson GD, Vician L, Herschman HR (2001). Synaptotagmin IV: biochemistry, genetics, behavior, and possible links to human psychiatric disease. Mol Neurobiol 23: 173–185.
Govek EE, Newey SE, Akerman CJ, Cross JR, Van der Veken L, Van Aelst L (2004). The X-linked mental retardation protein oligophrenin-1 is required for dendritic spine morphogenesis. Nat Neurosci 7: 364–372.
Grafstein-Dunn E, Young KH, Cockett MI, Khawaja XZ (2001). Regional distribution of regulators of G-protein signaling (RGS) 1, 2, 13, 14, 16, and GAIP messenger ribonucleic acids by in situ hybridization in rat brain. Brain Res Mol Brain Res 88: 113–123.
Guidotti A, Auta J, Davis JM, Di-Giorgi-Gerevini V, Dwivedi Y, Grayson DR et al (2000). Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 57: 1061–1069.
Gunnell D, Holly JM (2004). Insulin-like growth factors, insulin resistance and schizophrenia. Br J Psychiatry 185: 353–354.
Hashimoto K, Shimizu E, Komatsu N, Nakazato M, Okamura N, Watanabe H et al (2003). Increased levels of serum basic fibroblast growth factor in schizophrenia. Psychiatry Res 120: 211–218.
Hoffman DC, Donovan H (1995). Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effects liability. Psychopharmacology 120: 128–133.
Hubbell E, Liu W, Mei R (2002). Robust estimators for expression analysis. Bioinformatics 12: 1585–1592.
Hunter RG, Kuhar MJ (2003). CART peptides as targets for CNS drug development. Curr Drug Targets CNS Neurol Disord 2: 201–205.
Iritani S, Kuroki N, Ikeda K, Kazamatsuri H (1999). Calbindin immunoreactivity in the hippocampal formation and neocortex of schizophrenics. Prog Neuropsychopharmacol Biol Psychiatry 23: 409–421.
Iriye TT, Simmonds FA (1971a). Effect of tranquilizers and antidepressants on glycogen phosphorylase of rat brain. Biochem Pharmacol 20: 1889–1900.
Iriye TT, Simmonds FA (1971b). Possible involvement of glycogen phosphorylase of brain in the affective states. Int Pharmacopsychiatry 6: 98–110.
Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U et al (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4: 249–264.
Javitt DC (2004). Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9: 984–997.
Jung SK, Hong MS, Suh GJ, Jin SY, Lee HJ, Kim BS et al (2004). Association between polymorphism in intron 1 of cocaine- and amphetamine-regulated transcript gene with alcoholism, but not with bipolar disorder and schizophrenia in Korean population. Neurosci Lett 365: 54–57.
Kehrl JH, Sinnarajah S (2002). RGS2: a multifunctional regulator of G-protein signaling. Int J Biochem Cell Biol 34: 432–438.
Kontkanen O, Toronen P, Lakso M, Wong G, Castren E (2002). Antipsychotic drug treatment induces differential gene expression in the rat cortex. J Neurochem 83: 1043–1053.
Ktenas TB, Sotiroudis TG, Oikonomakos NG, Evangelopoulos AE (1978). Effect of phenothiazines on the activity of glycogen phosphorylase b. FEBS Lett 88: 313–316.
Kusumi I, Takahashi Y, Suzuki K, Kameda K, Koyama T (2000). Differential effects of subchronic treatments with atypical antipsychotic drugs on dopamine D2 and serotonin 5-HT2A receptors in the rat brain. J Neural Transmission 107: 295–302.
Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS et al, HGDH Study Group (2005). Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 62: 361–370.
Lipsky RH, Goldman D (2003). Genomics and variation of ionotropic glutamate receptors. Ann NY Acad Sci 1003: 22–35.
MacDonald ML, Eaton ME, Dudman JT, Konradi C (2005). Antipsychotic drugs elevate mRNA levels of presynaptic proteins in the frontal cortex of the rat. Biol Psych 57: 1041–1051.
Meyer JM, Nasrallah HS (eds) (2003). Medical Illness and Schizophrenia. American Psychiatric Publications, Inc.: Washington, DC.
Mirnics K, Middleton FA, Marquez A, Lewis DA, Levitt P (2000). Molecular characterization of schizophrenia viewed by microarray analysis of gene expression in prefrontal cortex. Neuron 28: 53–67.
Mirnics K, Middleton FA, Stanwood GD, Lewis DA, Levitt P (2001). Disease-specific changes in regulator of G-protein signaling 4 (RGS4) expression in schizophrenia. Mol Psych 6: 293–301.
Muma NA, Mariyappa R, Williams K, Lee JM (2003). Differences in regional and subcellular localization of G(q/11) and RGS4 protein levels in Alzheimer's disease: correlation with muscarinic M1 receptor binding parameters. Synapse 47: 58–65.
Norton N, Williams HJ, Williams NM, Spurlock G, Zammit S, Jones G et al (2003). Mutation screening of the Homer gene family and association analysis in schizophrenia. Am J Med Genet B Neuropsychiatr Genet 120: 18–21.
Ovalle S, Zamanillo D, Andreu F, Farre AJ, Guitart X (2001). Fibroblast growth factor-2 is selectively modulated in the rat brain by E-5842, a preferential sigma-1 receptor ligand and putative atypical antipsychotic. Eur J Neurosci 13: 909–915.
Pfeiffer-Guglielmi B, Fleckenstein B, Jung G, Hamprecht B (2003). Immunocytochemical localization of glycogen phosphorylase isozymes in rat nervous tissues by using isozyme-specific antibodies. J Neurochem 85: 73–81.
Polese D, de Serpis AA, Ambesi-Impiombato A, Muscettola G, de Bartolomeis A (2002). Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine. Neuropsychopharmacology 27: 906–913.
Riva MA, Molteni R, Tascedda F, Massironi A, Racagni G (1999). Selective modulation of fibroblast growth factor-2 expression in the rat brain by the atypical antipsychotic clozapine. Neuropharmacology 38: 1075–1082.
Schägger H, von Jagow G (1987). Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis for the separation of proteins in the range from 1–100 kDa. Anal Biochem 166: 368–379.
Siderovski DP, Heximer SP, Forsdyke DR (1994). A human gene encoding a putative basic helix–loop–helix phosphoprotein whose mRNA increases rapidly in cycloheximide-treated blood mononuclear cells. DNA Cell Biol 13: 125–147.
Stone WS, Faraone SV, Su J, Tarbox SI, Van Eerdewegh P, Tsuang MT (2004). Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am J Med Genet B Neuropsychiatr Genet 127: 5–10.
Tarazi FI, Baldessarini RJ, Kula NS, Zhang K (2003). Long-term effects of olanzapine, risperidone, and quetiapine on ionotropic glutamate receptor types: implications for antipsychotic drug treatment. J Pharmacol Exp Ther 306: 1145–1151.
Taymans JM, Leysen JE, Langlois X (2003). Striatal gene expression of RGS2 and RGS4 is specifically mediated by dopamine D1 and D2 receptors: clues for RGS2 and RGS4 functions. J Neurochem 84: 1118–1127.
Thomas EA, George RC, Danielson PE, Nelson PA, Warren AJ, Lo D et al (2003). Antipsychotic drug treatment alters expression of mRNAs encoding lipid metabolism-related proteins. Mol Psychiatry 8: 983–993, 950.
Timmerman W, Heijmen M, Westerink BH, Bruggeman R, den Boer JA (1999). Effects of acute and chronic administration of olanzapine in comparison to clozapine and haloperidol on extracellular recordings of substantia nigra reticulata neurons in the rat brain. Psychopharmacology (Berlin) 144: 286–294.
Toriumi C, Imai K (2003). Altered expression of insulins I and II and their mRNAs in the islets of Langerhans in dexamethasone-induced diabetic rats. Biomed Chromatogr 17: 26–32.
Tsuang MT, Nossova N, Yager T, Tsuang MM, Guo SC, Shyu KG et al (2005). Assessing the validity of blood-based gene expression profiles for the classification of schizophrenia and bipolar disorder: a preliminary report. Am J Med Genet B Neuropsychiatr Genet 133: 1–5.
Turek FW, Joshu C, Kohsaka A, Lin E, Ivanova G, McDearmon E et al (2005). Obesity and metabolic syndrome in circadian clock mutant mice. Science 308: 1043–1045.
VanderVorst A (2004). Homer: expression in chick ciliary ganglia. Saltman Q 1: 20–22.
Wang H, Chu W, Das SK, Ren Q, Hasstedt SJ, Elbein SC (2002). Liver pyruvate kinase polymorphisms are associated with type 2 diabetes in northern European Caucasians. Diabetes 51: 2861–2865.
Wang HD, Deutch AY (2004). Olanzapine reverses dopamine depletion-induced dendritic spine loss in prefrontal cortical pyramidal neurons. 34th Annual Meeting of Society for Neuroscience, San Diego, CA.
Wang RY, Liang X, Jardemark KE, Arvanov V (2000). Facilitation of NMDA transmission by olanzapine. In: Tran PV, Bymaster FP, Tye N, Herrera JM, Breier A, Tollefson GD (eds). Olanzapine (Zyprexa): A Novel Antipsychotic. Lippincott, Williams and Wilkins: Baltimore, MD. pp 114–136.
Wu Z, Irizarry R, Gentleman R, Murillo F, Spencer F (2004). A model based background adjustment for oligonucleotide expression arrays. Technical report, Johns Hopkins University. Department of Biostatistics working papers, Baltimore, MD.
Acknowledgements
We appreciate the grant support provided by Stanley Medical Research Institute (SHF), the gift of olanzapine by Eli Lilly and Company, and the secretarial assistance by Ms L Iversen. Some of the data published in this manuscript were presented at International Congress of Schizophrenia, held at Savannah, Georgia and the Pharmacogenomics in Psychiatry Meeting at the Zucker Hillside Hospital in Glen Oaks, NY, in April of 2005.
Author information
Authors and Affiliations
Corresponding author
Additional information
Supplementary Information accompanies the paper on Neuropsychopharmacology website (http://www.nature.com/npp).
Supplementary information
Rights and permissions
About this article
Cite this article
Fatemi, S., Reutiman, T., Folsom, T. et al. Chronic Olanzapine Treatment Causes Differential Expression of Genes in Frontal Cortex of Rats as Revealed by DNA Microarray Technique. Neuropsychopharmacol 31, 1888–1899 (2006). https://doi.org/10.1038/sj.npp.1301002
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sj.npp.1301002
Keywords
This article is cited by
-
Diagnosis and Drug Prediction of Parkinson’s Disease Based on Immune-Related Genes
Journal of Molecular Neuroscience (2022)
-
Changed frontal pole gene expression suggest altered interplay between neurotransmitter, developmental, and inflammatory pathways in schizophrenia
npj Schizophrenia (2018)
-
Mice that lack the C-terminal region of Reelin exhibit behavioral abnormalities related to neuropsychiatric disorders
Scientific Reports (2016)
-
Increased cortical expression of the zinc transporter SLC39A12 suggests a breakdown in zinc cellular homeostasis as part of the pathophysiology of schizophrenia
npj Schizophrenia (2016)
-
Neurotoxocarosis alters myelin protein gene transcription and expression
Parasitology Research (2015)
